The Driscoll Firm, LLC, is now accepting cases involving serious allergic reactions, including anaphylaxis, among adult dialysis patients who were administered the Omontys anemia drug.
The U.S. Food and Drug Administration (FDA) and several news agencies reported on February 23, 2013, that California-based Affymax, Inc., and Japan-based Takeda Pharmaceutical Company Limited had issued a voluntary recall of Omontys due to severe hypersensitivity reactions among some patients, including deaths.
If you or a loved one has suffered any adverse reactions that you believe are linked to Omontys, The Driscoll Firm, LLC, is here to help you. Contact us today by calling our toll-free number or using our online form. We provide free consultations. We can review your case and discuss the legal options available to you.
Why Was the Omontys Anemia Drug Recalled?
According to the FDA, Omontys (peginesatide) is a drug administered intravenously for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. More than 25,000 patients have received the drug since it hit the U.S. market.
The FDA says that reports have emerged of patients’ suffering allergic reactions to Omontys, including potentially life-threatening and fatal anaphylaxis, or a whole-body allergic reaction.
The FDA has received 19 reports of anaphylaxis from dialysis centers in the U.S., Reuters reports. The FDA says that fatal reactions have been reported in 0.02 percent of patients after their first dose of Omontys. The hypersensitivity reactions have occurred within 30 minutes of the intravenous administration of the drug, the FDA says.
Affymax and Takeda have sent letters to health care professionals, telling them that no new or existing patients should receive Omontys, the FDA says. The voluntary recall issued by the companies includes all existing lots of the product.
Get Legal Help from an Experienced Drug Injury Lawyer
Drug manufacturers and distributors owe a duty to provide only tested, safe and effective products. When they fail in their duty, and patients suffer serious health issues or death as a result, those companies need to be held fully accountable.
If you or a loved one is a dialysis patient who has been harmed after being administered the Omontys anemia drug, contact The Driscoll Firm, LLC, today. Call our toll-free number or fill out our online form. Our attorneys are committed to protecting patients’ rights and are experienced at taking on major corporations and drug manufacturers to secure the compensation our clients deserve. We can provide a free initial consultation and get to work on your case today.
For more information:
- Affymax, Takeda Recall Anemia Drug Omontys After Deaths, Reuters
- Omontys (peginesatide) Injection by Affymax and Takeda: Recall of All Lots – Serious Hypersensitivity Reactions, U.S. Food and Drug Administration